Tumors are characterized by either tumor vessel or stromal vessel phenotypes, which reportedly define how tumors responds to VEGFR2 antibody treatment. In this study, researchers seek to understand whether the tumor phenotypes associate with vascular response to VEGFR tyrosine kinase inhibitors (TKI) or if changes in vascular function are associated with changes in tumor size. Stromal vessel phenotype Calu-3 and tumor vessel phenotype Calu-6 cells were treated with cediranib for 5 days. Following treatment, cediranib decreased Calu-3 tumor perfusion and hypoxia significantly increased; however, neither of these factors were affected in Calu-6 tumors. These findings suggest that tumor stromal phenotypes associate more with acute tumor vascular response to VEGFR TKI. [LINK]
The Calu-6 cell line was established from the lung tissue of a 61-year-old Caucasian female who had been suffering from anaplastic carcinoma. Calu-6 cells are tumorigenic and have a modal chromosome number of 59. They also exhibit adherent cultural properties and display an epithelial morphology. The Calu-6 cell line is a suitable transfection host for in vivo and in vitro methods to study lung cancer, and a Calu-6 Transfection Reagent can be purchased through Altogen Biosystems to transfect Calu-6 cells. A Calu-6 xenograft model can be found here .
Comments
Post a Comment